Mots-c

Beskrivelse

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene. It translocates to the nucleus under metabolic stress or exercise to regulate gene expression, particularly genes involved in energy metabolism, fat oxidation, and stress adaptation. MOTS-c acts as a retrograde signaling molecule, influencing nuclear gene transcription via the AMPK pathway and other metabolic regulators, helping maintain mitochondrial homeostasis, improve insulin sensitivity, and enhance cellular resilience.

Preclinical studies (primarily in mice and cell models) show that MOTS-c:

• Increases fat oxidation and energy expenditure
• Improves insulin sensitivity and glucose uptake in skeletal muscle
• Mimics exercise-like effects (enhanced endurance, reduced fat accumulation)
• Protects against diet-induced obesity and insulin resistance
• Reduces inflammatory markers and oxidative stress
• Supports bone health and muscle function in aging models
• Exhibits potential anti-aging effects through metabolic reprogramming

In wellness, longevity, and performance communities, MOTS-c is researched via subcutaneous injection (typical anecdotal/research doses 5–10 mg weekly or 1–5 mg daily, often cycled 4–8 weeks on / 4 weeks off) for purported benefits including better metabolic flexibility, increased exercise capacity, fat loss support, improved recovery, and overall vitality—especially when combined with training, caloric control, and other mitochondrial-support interventions (e.g., NAD+ boosters, CoQ10). Users often report enhanced energy, better body composition, and improved endurance over weeks to months.

While mechanistic and animal data are promising, MOTS-c is not FDA-approved for any therapeutic, metabolic, anti-aging, performance enhancement, or medical use as of 2026—no large-scale human clinical trials have been completed to confirm efficacy, optimal dosing, safety, or long-term outcomes in people. Evidence is limited to preclinical studies, early mechanistic research, and widespread anecdotal/user reports from biohacking communities. Potential risks include injection-site reactions, unknown immunogenicity, possible metabolic imbalances with chronic use, or off-target effects on mitochondrial signaling. MOTS-c is prohibited by WADA for athletes and faces strict regulatory restrictions in most countries.

Never use MOTS-c without direct supervision from a qualified healthcare provider experienced in peptide and mitochondrial therapies. Self-administration carries significant risks of contamination from unregulated sources, incorrect dosing, adverse reactions, or legal issues. Prioritize evidence-based strategies—exercise, balanced nutrition, sleep, and approved medical interventions—for metabolic health, longevity, or performance goals. Consult a professional for personalized assessment, proper sourcing (from reputable compounding pharmacies if permitted), and to stay updated on any emerging human research or regulatory changes. MOTS-c is strictly investigational and not a substitute for proven therapies.